Cna Financial Corp Ultragenyx Pharmaceutical Inc. Transaction History

Cna Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$39.96 - $66.14 $16,783 - $27,778	420 Added 8.59%	5,310 $220,000
Q2 2022 Aug 09, 2022	SELL	$45.8 - $85.4 $29,312 - $54,656	-640 Reduced 11.57%	4,890 $292,000
Q1 2022 May 10, 2022	SELL	$62.2 - $84.4 $2,488 - $3,376	-40 Reduced 0.72%	5,530 $402,000
Q4 2021 Feb 11, 2022	BUY	$73.71 - $87.86 $28,746 - $34,265	390 Added 7.53%	5,570 $468,000
Q3 2021 Nov 12, 2021	SELL	$77.92 - $102.4 $125,451 - $164,864	-1,610 Reduced 23.71%	5,180 $467,000
Q2 2021 Aug 12, 2021	SELL	$92.19 - $115.71 $15,672 - $19,670	-170 Reduced 2.44%	6,790 $647,000
Q1 2021 May 14, 2021	SELL	$106.9 - $167.73 $33,139 - $51,996	-310 Reduced 4.26%	6,960 $792,000
Q4 2020 Feb 12, 2021	SELL	$84.4 - $177.39 $73,428 - $154,329	-870 Reduced 10.69%	7,270 $1.01 Million
Q3 2020 Nov 12, 2020	BUY	$72.98 - $90.0 $729 - $900	10 Added 0.12%	8,140 $669,000
Q2 2020 Aug 13, 2020	BUY	$46.91 - $78.22 $381,378 - $635,928	8,130 New	8,130 $636,000

345

86.7M

675K

846K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.72B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.